The patents cover utilization of PCADM-1 antibodies and associated methods for monitoring PCADM-1 in patients for diagnosing and monitoring prostate cancer disease.
PCADM-1 is capable of detecting prostate cancer cells irrespective of whether they are androgen receptor (AR) negative or positive enabling it to detect cancer cell populations that might go undetected in PSA testing. A patent for this AR component was filed in June 2015.
Besides patents in the US, this technology is supported by published patents in the following countries:
- Great Britain